Stand Up to Cancer is teaming with Microsoft and SITC to provide a new round of $11 million in grants to study cancer immunotherapies.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
From targeted metagenomics on almost 300 soil samples, researchers saw evidence for microbiome gene clusters associated with natural product biosynthesis in NYC parks.
The partners will combine genome editing approaches with Watson's computational and machine learning methods to study drug-resistance in tumors.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The researchers identified 122 potential immune response drivers that could serve as targets for drug research efforts.
The researchers identified new combinations of mutated genes and drugs that could provide the platform for future cancer therapies.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.